نبذة مختصرة : Introduction. Chronic Obstructive Pulmonary Disease (COPD) is a not transmissible disease, characterized by a limitation of airflow in the respiratory tract, due to an abnormal immune response to particles. Objective. This article aims to show that the application of budesonide / formoterol improves lung capacity in people over 40 years with Chronic Obstructive Pulmonary Disease. Materials and methods. A systematic review was conducted in the period between 2000 and 2018 in different databases where clinical trials were included. Four articles were identified for the final analysis. Results. During the comparative evaluation of budesonide with formoterol, a total of 709 people were evaluated, with an average age of 53.5 years, 65.4% were male, 21% reported not having used tobacco, all with a diagnosis of moderate-severe Chronic Obstructive Pulmonary Disease according to the GOLD scale (Global Initiative For Chronic Obstrutive Lung Disease). The studies determined that when budesonide / formoterol of 400/12 mcg and 320/9 mcg was administered, the patients had a slight improvement in the Forced Expiratory Volume of the first second (FEV1). Only two patients presented adverse effects. However, for the results mentioned above no significant differences were found. Conclusions. The use of budesonide / formoterol is effective in improving pulmonary ventilatory capacity, decreases the number of annual exacerbations and generates adequate control of symptoms, however, it is equally effective in fluticasone / salmeterol. ; Introducción. La Enfermedad Pulmonar Obstructiva Crónica (EPOC) es una patología no transmisible, caracterizada por una limitación de flujo de aire en las vías respiratorias debido a una respuesta inmunológica anormal frente a partículas. Objetivo. Conocer la eficacia que tiene la budesonida/formoterol comparado con la fluticasona/salmeterol en la mejoría de la capacidad pulmonar en personas mayores de 40 años con Enfermedad Pulmonar Obstructiva Crónica. Materiales y métodos. Se realizó una revisión ...
Relation: https://revistasdigitales.uniboyaca.edu.co/index.php/rs/article/view/369/489; Wilt TJ, Niewoehner D, MacDonald R, Kane RL. Management of stable chronic obstructive pulmonary disease: a systematic review for a clinical practice guideline. Ann Intern Med [Internet]. 2007 Nov 6 [cited 2019 Mar 11];147(9):639–53. Disponible en: https://doi.org/10.7326/0003-4819-147-9-200711060-00009 2. Brett AS, Al-Hasan MN. COPD Exacerbations — A Target for Antibiotic Stewardship. N Engl J Med [Internet]. 2019 Jul 11 [cited 2019 Jul 18];381(2):174–5. Disponible en: https://doi.org/10.1056/NEJMe1905520 3. Soriano JB. The evolution of COPD species; or, something is changing for good in COPD. Eur Respir J [Internet]. 2019 Jun 27 [cited 2019 Jul 18];53(6):1900762. Disponible en: https://doi.org/10.1183/13993003.00762-2019. 4. Zhang L, Feng W, Lu BB, Li N, Li H, Gu SH, et al. [The impact of ambient PM(2.5) on daily outpatient visits due to chronic obstructive pulmonary disease, among the urban residents of Ningbo city]. Zhonghua Liu Xing Bing Xue Za Zhi [Internet]. 2019 Jun 10 [cited 2019 Jul 18];40(6):686–91. Disponible en: https://doi.org/10.3760/cma.j.issn.0254-6450.2019.06.016 5. Karoli NA, Rebrov AP. Endothelial dysfunction in patients with chronic obstructive pulmonary disease in combination with coronary heart disease. Ter Arkh [Internet]. 2019 Mar 29 [cited 2019 Jul 18];91(3):22–6. Disponible en: https://doi.org/10.26442/00403660.2019.03.000061 6. Grigoryeva NY, Maiorova МV, Korolyova ME, Samolyuk MO. Сomorbidity and polymorbidity of the patient with chronic obstructive pulmonary disease and cardiovascular diseases. Ter Arkh [Internet]. 2019 Mar 10 [cited 2019 Jul 18];91(1):38–47. Disponible en: https://doi.org/10.26442/00403660.2019.01.000027 7. Hurst JR, Vestbo J, Anzueto A, Locantore N, Müllerova H, Tal-Singer R, et al. Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease. N Engl J Med [Internet]. 2010 Sep 16 [cited 2019 Mar 11];363(12):1128–38. Disponible en: https://doi.org/10.1056/NEJMoa0909883 8. Vestbo J, Hurd SS, Agustí AG, Jones PW, Vogelmeier C, Anzueto A, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med [Internet]. 2013 Feb 15 [cited 2019 Mar 11];187(4):347–65. Disponible en: https://doi.org/10.1164/rccm.201204-0596PP 9. Belenkov YN, Tsvetkova OA, Privalova E V., An G V., Ilgisonis IS, Voronkova OO. Comorbidity of Chronic Obstructive Pulmonary Disease and Cardiovascular Diseases: Place of Therapy with Modern β-Adrenoblockers. Kardiologiia [Internet]. 2019 Jun 27 [cited 2019 Jul 18];59(6):48–55. Disponible en: https://doi.org/10.18087/cardio.2019.6.n458 10. Peces-Barba G, Barberà JA, Agustí A, Casanova C, Casas A, Izquierdo JL, et al. [Diagnosis and management of chronic obstructive pulmonary disease: joint guidelines of the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) and the Latin American Thoracic Society (ALAT)]. Arch Bronconeumol [Internet]. 2008 May [cited 2019 Mar 11];44(5):271–81. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/18448019 11. Holleman DR, Simel DL, Goldberg JS. Diagnosis of obstructive airways disease from the clinical examination. J Gen Intern Med [Internet]. 1993 Feb [cited 2019 Mar 12];8(2):63–8. Disponible en: https://doi.org/10.1007/BF02599985 12. Mathers CD, Loncar D. Projections of Global Mortality and Burden of Disease from 2002 to 2030. Samet J, editor. PLoS Med [Internet]. 2006 Nov 28 [cited 2019 Mar 12];3(11):e442. Disponible en: https://doi.org/10.1371/journal.pmed.0030442 13. Mirza S, Clay RD, Koslow MA, Scanlon PD. COPD Guidelines: A Review of the 2018 GOLD Report. Mayo Clin Proc [Internet]. 2018 Oct 1 [cited 2019 Mar 12];93(10):1488–502. Disponible en: https://doi.org/10.1016/j.mayocp.2018.05.026 14. Gibson GJ, Loddenkemper R, Lundbäck B, Sibille Y. Respiratory health and disease in Europe: the new European Lung White Book. Eur Respir J [Internet]. 2013 Sep 2 [cited 2019 Mar 12];42(3):559–63. Disponible en: https://doi.org/10.1183/09031936.00105513 15. Avdeev SN, Trushenko NV. New opportunities of dual bronchodilation therapy for patients with chronic obstructive pulmonary disease. Ter Arkh [Internet]. 2019 Mar 30 [cited 2019 Jul 18];91(3):76–85. Disponible en: https://doi.org/10.26442/00403660.2019.03.000136 16. Kew KM, Dias S, Cates CJ. Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis. Cochrane Database Syst Rev [Internet]. 2014 Mar 26 [cited 2019 Mar 12];(3):CD010844. Disponible en: https://doi.org/10.1002/14651858.CD010844.pub2 17. Cohen J. A Coefficient of Agreement for Nominal Scales. Educ Psychol Meas [Internet]. 1960 Apr 2 [cited 2019 Jul 18];20(1):37–46. Disponible en: https://doi.org/10.1177/001316446002000104 18. Campo-Arias A, Herazo E. Concordancia intra-e interevaluadores. Rev Colomb Psiquiat [Internet]. 2010 [cited 2019 Jul 18];39(2):423–32. Disponible en: http://www.redalyc.org/pdf/806/80615447015.pdf 19. Tang W, Hu J, Zhang H, Wu P, He H. Kappa coefficient: a popular measure of rater agreement. Shanghai Arch Psychiatry. 2015;27(1):62–7. https://doi.org/10.11919/j.issn.1002-0829.215010 20. Cazzola M, Santus P, Di Marco F, Boveri B, Castagna F, Carlucci P, et al. Bronchodilator effect of an inhaled combination therapy with salmeterol + fluticasone and formoterol + budesonide in patients with COPD. Respir Med [Internet]. 2003 May [cited 2019 Jun 30];97(5):453–7. Disponible en: https://doi.org/10.1053/rmed.2002.1455 21. Lindberg A, Szalai Z, Pullerits T, Radeczky E. Fast onset of effect of budesonide/formoterol versus salmeterol/fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstruction. Respirology [Internet]. 2007 Sep [cited 2019 Jun 30];12(5):732–9. Disponible en: https://doi.org/10.1111/j.1440-1843.2007.01132.x 22. Partridge MR, Schuermann W, Beckman O, Persson T, Polanowski T. Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD. Ther Adv Respir Dis [Internet]. 2009 Aug 4 [cited 2019 Jun 30];3(4):147–57. Disponible en: https://doi.org/10.1177/1753465809344870 23. Dalby C, Polanowski T, Larsson T, Borgström L, Edsbäcker S, Harrison TW. The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. Respir Res [Internet]. 2009 Oct 31 [cited 2019 Jul 1];10(1):104. Disponible en: https://doi.org/10.1186/1465-9921-10-104 24. World Health Organization. WMA Declaration of Helsinki – Ethical Principles for Medical Research Involving Human Subjects – WMA – The World Medical Association [Internet]. Helsinky; 2013 [cited 2019 Jul 18]. Disponible en: https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/; https://revistasdigitales.uniboyaca.edu.co/index.php/rs/article/view/369
Processing Request
No Comments.